Michael Grayling

Associate Researcher

Population Health Sciences Institute

Biography

Background

I was a Newcastle University Research Fellow at Newcastle University from 2018 to 2022. Prior to this I was a statistician at the MRC Biostatistics Unit, University of Cambridge.

I am now a principal statistician at Janssen. I remain an associate researcher at Newcastle University and supervise a number of PhD students in the BRG.

I am interested in the design and analysis of clinical trials. My work has involved a mixture of developing novel statistical methodology for trials, comparing existing method performance, and collaborating on real trials. I also work on developing user-friendly software for trial design; I created and maintain the multiarm app for designing fixed-sample and adaptive (group-sequential/drop-the-losers) multi-arm trials, available here.

PhD students

Ruqayya Azher (Primary supervisor: James Wason)
Laura Etfer
Aritra Mukherjee (Primary supervisor: James Wason)
Luke Ouma (Primary supervisor: James Wason)
Samuel Sarkodie

Contact

Email: michael.grayling@ncl.ac.uk
Telephone: +44 (0) 191 208 3699
Address: Population Health Sciences Institute, 4th Floor Ridley Building 1, Queen Victoria Road, Newcastle upon Tyne NE1 7RU, UK

Interests

Adaptive design
Early phase oncology trials
Crossover trials
Stepped-wedge trials

Education

Wellcome Trust PhD Programme in Mathematical Genomics and Medicine, 2012-16
MRC Biostatistics Unit, University of Cambridge
Systems Biology MSci, 2011-12
University of Cambridge
Mathematics BA (Hons), 2008-11
University of Cambridge

Publications

Quickly discover relevant content by filtering publications.

Michael J Grayling, James MS Wason (2022). Point estimation following a two-stage group sequential trial. Statistical Methods in Medical Research.

Luke O. Ouma, Michael J. Grayling, James M. S. Wason, Haiyan Zheng (2022). Bayesian modelling strategies for borrowing of information in randomised basket trials. Journal of the Royal Statistical Society: Series C (Applied Statistics).

Luke O. Ouma, James M. S. Wason, Haiyan Zheng, Nina Wilson, Michael Grayling (2022). Design and analysis of umbrella trials: Where do we stand?. Frontiers in Medicine.

S. Faye Williamson, Michael J. Grayling, Adrian P. Mander, Nurulamin M. Noor, Joshua S. Savage, Christina Yap, James M. S. Wason (2022). Subgroup analyses in randomized controlled trials frequently categorized continuous subgroup information. Journal of Clinical Epidemiology.

Samuel K Sarkodie, James MS Wason, Michael J Grayling (2022). A hybrid approach to comparing parallel-group and stepped-wedge cluster-randomized trials with a continuous primary outcome when there is uncertainty in the intra-cluster correlation. Clinical Trials.

Haiyan Zheng, Michael J Grayling, Pavel Mozgunov, Thomas Jaki, James M S Wason (2022). Bayesian sample size determination in basket trials borrowing information between subsets. Biostatistics.

Aritra Mukherjee, Michael J. Grayling, James M. S. Wason (2022). Adaptive Designs: Benefits and Cautions for Neurosurgery Trials. World Neurosurgery.

Aritra Mukherjee, James M. S. Wason, Michael J. Grayling (2022). When is a two-stage single-arm trial efficient? An evaluation of the impact of outcome delay. European Journal of Cancer.

Michael J. Grayling, Adrian P. Mander (2022). Optimised point estimators for multi-stage single-arm phase II oncology trials. Journal of Biopharmaceutical Statistics.

Michael J. Grayling, Martina McMenamin, Robert Chandler, Rakesh Heer, James M. S. Wason (2022). Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials. BMC Cancer.

Michael J. Grayling, James M. S. Wason, Sofía S. Villar (2022). Response adaptive intervention allocation in stepped-wedge cluster randomized trials. Statistics in Medicine.

Michael J. Grayling, Adrian P. Mander (2021). Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported Adequately. JCO Precision Oncology.

Grayling MJ, Bigirumurame T, Cherlin S, Ouma L, Zheng H, Wason J (2021). Innovative trial approaches in immune-mediated inflammatory diseases: Current use and future potential. BMC Rheumatol 2021; 5:21.

Grayling MJ, Mander AP (2021). Accounting for variation in the required sample size in the design of group-sequential trials. Contemp Clin Trials 2021; 107:106459.

Kunzmann K, Grayling MJ, Lee KM, Robertson DS, Rufibach K, Wason JMS (2021). A review of Bayesian perspectives on sample size derivation for confirmatory trials. Am Stat 2021; DOI:10.1080/00031305.2021.1901782.

Ouma LO, Grayling MJ, Zheng H, Wason J (2021). Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods. Pharm Stat 2021; doi:10.1002/pst.2119.

Ward M, Grayling M, Wason J, Welton NJ, Haji-Ali AL, Jalal H, Thom H (2020). PSU4 Value of information for adaptive trials: Proof of concept study in multi-arm multi-stage trials of interventions for the prevention of surgical site infections. Value Health 2020; 23:S738.

McClelland G, Wilson N, Shaw L, Grayling M, Haworth D, Price CI (2020). Ambulance documentation of stroke symptoms during the UK COVID-19 'Stay at Home' message. Emerg Med J 2020; 38:83-84.

McClelland G, Shaw G, Thompson L, Wilson N, Grayling M (2020). Impact of the COVID-19 lockdown on hangings attended by emergency medical services. Resuscitation 2020; 157:89-90.

Law M, Grayling MJ, Mander AP (2020). A stochastically curtailed two-arm randomised phase II trial design for binary outcomes. Pharm Stat 2020; 20:212-28.

See all publications